Clinical trials: ALK Fusion Protein Expression, open to volunteers
NSCLC Stage IV, ALK Fusion Protein Expression
Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC
The purpose of this study is to evaluate the safety of a cancer peptide vaccine to prevent or delay acquired resistance in advanced ALK+ lung cancer patients currently on ALK targeted therapy.
- Trial name
- ARCHER (NCT05950139)
- Testing
- Peptide vaccine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
ALK Fusion Protein Expression, Adjuvant Therapy
A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung Cancer
This randomized, active-controlled, multicenter, open-label, Phase II study is designed to evaluate the efficacy and safety of ensatinib compared with Platinum-Based Chemotherapy as adjuvant treatment in ALK fusion positive…
- Conditions
- ALK Fusion Protein Expression, Adjuvant Therapy, Non-Small Cell Lung Cancer
- Trial name
- NCT05186506
- Testing
- Ensatinib, chemotherapy
- Volunteers
- 152 people
- Sponsor
- Sichuan University